PATHOLOGY & ONCOLOGY RESEARCHVol. 10 No. 1, 2004

 Article

Increased Angiogenesis in Cutaneous T-cell Lymphomas

Grzegorz MAZUR1, Zdzislaw WOZNIAK2, Tomasz WRÓBEL1, Joanna MAJ3, Kazimierz KULICZKOWSKI1

1Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw, Poland
2Department of Pathology, Wroclaw, Poland
3Department of Dermatology and Venerology, Wroclaw, Poland

 

Primary cutaneous T-cell lymphomas (CTCL) represent a heterogeneous group of neoplasms derived from skin-homing T cells. CTCL behave similarly to indolent B-cell lymphomas. There is increasing evidence that angiogenesis may be important in lymphoproliferative disorders. The aim of the study was to evaluate microvessel density (MVD) as a parameter of tumor angiogenesis measured by the expression of CD34 in the skin samples in CTCL patients. Formaldehyde-fixed, paraffin-embedded skin tumor biopsy specimens from 25 patients (16 men, 9 women) with CTCL (mycosis fungoides), and 8 skin samples from healthy volunteers were analysed. The preparations were stained with haematoxylin and eosin, and evaluated histopathologically. Staining for endothelial cells with monoclonal antibody against CD34 revealed a mean number of 134 dots per mm2 for CTCL and 106 dots/mm2 for controls; the difference was statistically significant (p=0.0388). Our study shows a higher number of microvessels in primary CTCL compared with normal skin. Microvascular endothelial cells have become an important target in cancer therapy. Increased MVD in the skin of CTCL patients indicate that angiogenesis may play a role in the growth of CTCL, and raises the possibility of using angiogenesis inhibitors in CTCL therapy. Pathology & Oncology Research, Vol 10, Nr 1, 34-36, 2004

Key words: angiogenesis; microvessel density; cutaneous T-cell lymphoma; mycosis fungoides


Received: Jan 6, 2004; accepted: Feb 15, 2004
Correspondence: Grzegorz MAZUR, Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Pasteura 4 Wroclaw 50-367, Poland; Tel: +48 71 7842576, Fax: +48 71 7840112; E-mail: grzegmaz@hemat.am.wroc.pl

Click here to get the full-text version in PDF!
ad